At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
Juvéderm Volux XC is an injectable gel filler containing hyaluronic acid. The Food and Drug Administration (FDA) has approved Juvéderm ® Volux ™ XC for the improvement of jawline definition in ...
IRVINE, Calif., Jan. 18, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the highly anticipated national launch of JUVÉDERM ® VOLUX™ XC. The long-lasting ...
JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION IRVINE, Calif., Aug. 3, 2022 /PRNewswire/ -- Today, Allergan ...
(RTTNews) - Drug manufacturer AbbVie Inc. (ABBV), Tuesday announced that its subsidiary Allergan Aesthetics received approval from the U.S. Food and Drug Administration or FDA regarding Juvederm ...
Tutorials on how to get a “snatched” look are all over TikTok, whether it’s via the siren eyes makeup technique or using concealer to sculpt your face. But Juvéderm just announced that it’s launching ...
The Food and Drug Administration has approved the hyaluronic acid dermal filler Juvéderm Voluma XC for injection in the temple region to improve moderate to severe temple hallowing in individuals over ...
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVEDERM ® ULTRA ...
Consumers and new patients who receive aesthetic treatment from the JUVÉDERM ® Collection of Fillers, can also enroll in Allē, the Allergan Aesthetics loyalty rewards program to unlock access to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback